Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.
CEGF816X2102
Phase 1 other active
Quick answer
Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC. for Patients with EGFR-mutant Non Small Cell Lung Cancer is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Patients with EGFR-mutant Non Small Cell Lung Cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active